GlassScriptPhysician profile
Jill G Denowitz
NPI 1215013941
$6,116.24
in general payments reported to CMS, 2019-2025
42 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $644 · 2021: $976 · 2022: $736 · 2023: $876 · 2024: $651 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $830.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $703.05 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $660.79 | 2021-2025 | |
| Abbvie INC. | $630.41 | 2021-2023 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $549.46 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.91 | 2019-2025 | Jardiance |
| Allergan, INC. | $184.38 | 2019-2020 | |
| Amarin Pharma, INC. | $155.47 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $153.50 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.57 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $144.97 | 2019-2022 | |
| Medtronic Vascular, INC. | $132.47 | 2019 | |
| Exact Sciences Corporation | $118.32 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $106.69 | 2020-2021 | |
| Glaxosmithkline, LLC. | $105.11 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Denowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.